Strides Pharma's Chestnut Ridge Facility Features Voluntary Action Indicated Status

Strides Pharma Inc has received a positive inspection report from the USFDA for its Chestnut Ridge facility. The inspection covered Good Manufacturing Practices and a pre-approval check for drug-device combinations. The facility will support Strides Pharma's growth in the US market with innovative products.

Devdiscourse News Desk | New Delhi | Updated: 05-02-2026 13:32 IST | Created: 05-02-2026 13:32 IST

Strides Pharma's Chestnut Ridge Facility Features Voluntary Action Indicated Status — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Country:
India

Strides Pharma Science Ltd's subsidiary, Strides Pharma Inc, has announced a favorable inspection outcome for its Chestnut Ridge unit in New York, classified as voluntary action indicated (VAI) by the US FDA.

The inspection, conducted from December 17 to December 23, 2025, assessed current Good Manufacturing Practices (cGMP) and drug-device combination capabilities, focusing on recent filings in the nasal sprays category.

The successful closure of this inspection, which serves the US market, bodes well for Strides Pharma's future product lines, growth prospects, and strengthening business in the competitive pharmaceutical landscape.

(With inputs from agencies.)